U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07080567) titled 'Manipulating the Peri-Infarct Area Using Maraviroc to Enhance Motor Skills After Stroke' on July 02.
Brief Summary: MASTER is a single-center, patient and investigator-blinded, Randomized Controlled Trial (RCT) to compare the efficacy of Maraviroc, a C-C chemokine receptor 5 (CCR5) antagonist, against placebo regarding motor function and motor learning skills in the first 3 months after ischemic stroke.
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Ischemic Stroke
Stroke
Stroke Acute
Intervention:
DRUG: Maraviroc
Maraviroc (300mg) twice daily for 90 days
DRUG: Mannitol
Placebo intervention
Recruitment ...